Bozitinib enteric-coated capsules | China Drugs List

Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.

Company: Beijing Purunao Biotechnology Co., Ltd.
Medicine type: Chemical medicine
Therapeutic area: Oncology
Indications recorded in the public source: 1. Locally advanced or metastatic NSCLC with MET exon 14 skipping. 2. Locally advanced or metastatic NSCLC with MET amplification. 3. Adults with a PTPRZ1-MET fusion and IDH-mutant astrocytoma (WHO grade 4), or glioblastoma with a history of a lower-grade tumor, after failure of prior therapy.
Indication source and scope: Source date(s): 2026-07-15. Manufacturer prescribing information for Mainland China.
Prescribing-information limitations: Indications checked against an official public submission. The full original prescribing information is still unavailable.
China availability status: Historical Chinese approval verified; current continuous market availability has not been checked for every product.
Overseas status: Market-by-market verification pending.
Insurance classification: Included in national insurance (Category B)
Insurance edition: 2025 edition; effective 1 January 2026
Insurance restrictions: Limited to: 1. Locally advanced or metastatic NSCLC with MET exon 14 skipping. 2. Locally advanced or metastatic NSCLC with MET amplification. 3. Adults with a PTPRZ1-MET fusion and IDH-mutant astrocytoma (WHO grade 4), or glioblastoma with a history of a lower-grade tumor, after failure of prior therapy.
Insurance period: 2026-01-01 to 2026-12-31
Insurance verification notes: Matched by exact or normalized ingredient/formulation name. Reimbursement still depends on the dosage form and listed payment restrictions.

Sources

Open the interactive record, public price references and discussions